PharmAust is on track for Oral CV-19 treatment?

Hi ALL,

We have another lock down here in Perth.

Time for reflection, on where our company is and how far PharmAust is with Monepantel Vrs CV-19.

We have remarkable results from WEHI. Reference announcement 18th June 2020

"Walter and Eliza Hall Institute researcher Professor Marc Pellegrini (MBBS BSc FRACP PhD FAHMS), joint head of the Institute’s Infectious Diseases and Immune Defence division and an infectious disease clinician at the Royal Melbourne Hospital, stated, “These are encouraging anti-viral profiles. These exciting repeat results validate the results of the initial test and form strong grounds for progressing the drug to the next step. Demonstrating twice that infectivity of SARS-CoV-2 virus particles can be suppressed by up to approximately 95% in cell cultures is a remarkable outcome. We intend to continue collaborating with PharmAust with preclinical experimentation to support their progress.” (These statements are the considered view of the principal investigator based on his years of experience in this specialised discipline.)"



We had the results, reinforced by 360biolabs, refence announcement 9th September 2020


"In experiments conducted at 360biolabs, MPL and MPLS inhibited virus burden by up to 99% and 75%, respectively. The data for MPL were quite notably similar to the 100% inhibition demonstrated for remdesivir used as a positive control, although at differing concentrations of drug. Anti-viral activity by mTOR inhibitor rapamycin was not demonstrated at the concentrations tested by 360biolabs."

8 January 2021 – Perth, Australia: PharmAust Ltd (ASXAA), a clinical-stage oncology company, is working closely withDr Martijn van Hemert at Leiden University Medical Centre (LUMC) in the Netherlands as more research is being undertaken at LUMC to increase the solubility of MPL, as a precursor to MPL demonstrating applicability against coronavirus.
This involves finding conditions that are compatible with the highly specialised assays and coronavirus culture conditions for testing MPL. These assays and this development program are crucial for later performing work in more advanced human airway systems.

Combining the conditions required for the specialised cell-based assays at LUMC with the highly insoluble nature and unique features of MPL, means the standard assays used for other compounds require a unique high level of optimisation in MPL testing.

As announced on 28 May 2018, PharmAust successfully reformulated monepantel (MPL) from a liquid product to a tablet. As announced on 17 October 2017, part of the challenge in reformulation was addressing the poorly soluble nature of MPL in water.PharmAust’s clinical research plans, however, remain on track. As announced on 23 December 2020, MPL manufacture in preparation for research and development in Phase 1/2 clinical trials is ongoing with trials remaining due to commence later in CY 2021.

PharmAust’s Chief Scientific Officer Dr Richard Mollard stated, “PharmAust is delighted to have the opportunity to work with a researcher of the internationally recognised calibre of Dr Martijn van Hemert. Moving MPL forward as an antiviral weapon against COVID-19 is critical for the armamentarium being developed globally to fight this disease. The importance of this work may be best described by Dr van Hemert’s narrative during his recent European Parliamentary Research Interview about COVID-19 treatments1.” “PharmAust is grateful to the researchers who are presently working with disrupted global supply chains and under the Netherlands’ strictest COVID-19 associated lockdowns yet. These lockdowns have endured since 15 December 2020 and will remain in place until 19 January 2021. Researchers have done a fantastic job meeting these challenges and PharmAust will be pleased to update shareholders as results come to hand.”

Tom Flanagan

·News Reporter

Updated Tue, 2 February 2021, 5:15 am·3-min read

A leading coronavirus expert has warned there needs to be an urgency to vaccinate those in countries with limited or no supply to the vaccine to prevent a wave of mutant strains.

Dean of the School of Health at Brown University Dr Ashish Jha says the vaccine needs to be rolled out globally as a quickly as possible to “put this nightmare pandemic behind us”.

Taking to his Twitter account, Dr Jha said a rise of infections in underprivileged nations could lead to a surge in variants making current vaccines redundant.

“We could see rise of variants that can infect, cause outbreaks here and other vaccinated places, requiring us to update our vaccines and vaccinate everyone again,” he said.

“It’s the nightmare scenario of a never-ending pandemic.”

He branded calls for natural herd immunity as “so naive” and said without a vaccine that is not an effective method for moving forward.

“[Herd immunity advocates] literally advocated for virus to have more chances to mutate,” Dr Jha said.

In an interview with WebMD, Dr Jha said we need to be vaccinating people “as quickly as possible”.

“It’s probably our single most valuable tool in the short run.”

Dr Jha believes vaccines need to be rolled out quicker to prevent further mutant strains of the virus. Source: Getty

In Australia, the federal government have taken a less urgent approach to the vaccine rollout compared to nations like the US and the UK due to the low levels of infection in the community.

However, with mounting pressure from some experts amid a rise in virus leaks from hotel quarantine programs across the country, there is more potency now with the vaccine rollout which has been edged foward from initial plans and will now be rolled out at the end of this month.

Reminder to avoid ‘vaccine nationalism’

World Health Organisation Tedros Adhanom Ghebreyesus has repeatedly warned countries to avoid “vaccine nationalism” and stockpiling jabs for themselves.

It comes as the EU was forced to backtrack on plans to place a limit on vaccine exports to the UK as European nations fell behind many first world countries in their vaccine rollout.

“The world is watching and it is only through international collaboration that we will beat this pandemic,” Britain’s Foreign Secretary Dominic Raab said.

• 3000 doses of 'fake coronavirus vaccine' seized

• China shuts down viral video after anal Covid test accusation

• Study hints at devastating Covid consequence for men

  
  

  Study hints at harmful Covid consequence for men Covid-19 may damage sperm quality and reduce fertility in men, according to a new study.

  
  
  
  

In its bid to assist the global vaccination plan, Australia will provide $35.7 million to help vaccinate at least 1.5 million Cambodians against Covid-19.

The assistance package would significantly bolster Cambodian efforts in vaccinating 80 per cent of its 16 million people against the virus as soon as practicable, the Australian embassy and the Cambodian government announced on Monday.

"In recognition that nobody is safe until everyone is safe, our support is likely to help vaccinate at least 1.5 million Cambodians and will go a long way towards supporting widespread access to WHO-approved vaccines in Cambodia," Australian ambassador Pablo Kang said.

Can we here at PharmAust Ltd, take comfort in the amount of time, that it is taking to receive our results from Leiden?
My guess is yes - from reading what the Dr Jha above has written.
If they are going to require on going vaccine updates - year in year out, then we have plenty of time.

Remember, it's a never ending pandemic, so,when PharmAust commercialises MPL as a treatment, it may very well be an ongoing income stream for years to come. Just think about what revenue could be derived from a pill that treats you for CV-19. Hundreds of millions of dollars comes to mind.

PharmAust IMO, will have an oral treatment, with NO side affects, easily transportable, easy to handle and distribute over the counter at your pharmacy.

We are all in the same boat waiting for the results, which as stated - are imminent.
The suspense is killing us all, being patent, will equal reward.



As Always
Best
Mickey Mouse